Related by context. All words. (Click for frequent words.) 70 Phenoxodiol 64 YONDELIS 63 CoFactor 63 bortezomib 62 entinostat 62 INCB# [001] 62 Xanafide 62 pertuzumab 62 belinostat 62 decitabine 62 #D#C# 61 depsipeptide 61 enzastaurin 61 eniluracil 61 BAY #-# 61 elesclomol 61 PXD# 61 CBLC# 61 obatoclax 60 Bezielle 60 ELACYT 60 HGS# 60 raltegravir 60 Amrubicin 60 neratinib 60 MEK inhibitors 60 MGCD# [001] 60 Sym# 60 temsirolimus 60 voreloxin 60 angiogenesis inhibitor 60 abiraterone 60 IMC A# 60 elotuzumab 60 BRAF inhibitor 60 phase IIb clinical 60 Symadex 60 AEG# 60 Bortezomib 60 CD# antibody [001] 60 castration resistant prostate cancer 60 pan HDAC inhibitor 60 XmAb# 60 trastuzumab Herceptin 60 mapatumumab 59 recurrent ovarian cancer 59 sorafenib 59 docetaxel 59 LY# [003] 59 ganetespib 59 HuMax CD4 59 ATL# [001] 59 Gefitinib 59 tanespimycin 59 Telcyta 59 anticancer agent 59 HGS ETR1 59 Seliciclib 59 dasatinib 59 picoplatin 59 Targretin 59 HER2 positive metastatic breast 59 imetelstat 59 GRN#L 59 nitazoxanide 59 lapatinib 59 Trastuzumab 59 Ceflatonin 59 trabectedin 59 alvespimycin 59 tyrosine kinase inhibitor 59 liposomal doxorubicin 59 romidepsin 59 Aplidin 59 fulvestrant 59 tocilizumab 59 Neuradiab 59 tremelimumab 59 cytotoxic 58 Omacetaxine 58 HER2 positive breast cancer 58 sunitinib 58 MEK inhibitor 58 zanolimumab 58 elacytarabine 58 EOquin 58 OncoVEX GM CSF 58 PSMA ADC 58 abiraterone acetate 58 Erlotinib 58 Asentar 58 Zolinza 58 cilengitide 58 MGd 58 vorinostat 58 Triapine 58 humanized antibody 58 anti leukemic 58 AEGR 58 therapeutic monoclonal antibody 58 olaparib 58 IMA# 58 PLX# 58 EndoTAG TM -1 58 lapatinib Tykerb 58 Bicifadine 58 anticancer compound 58 proteasome inhibitors 58 valopicitabine 58 chemotherapeutic drug 58 sirolimus 58 epothilone 58 molecularly targeted 58 IMC #B 58 Vandetanib 58 Hycamtin 58 thymalfasin 58 antibody MAb 58 ixabepilone 58 MAGE A3 ASCI 58 tesmilifene 58 AQ4N 58 Taxotere ® 58 liposomal formulation 58 Degarelix 58 Amplimexon 58 galiximab 58 indibulin 58 metastatic renal cell carcinoma 58 docetaxel chemotherapy 58 Insegia 58 goserelin 58 sorafenib Nexavar 58 CYT# 58 endocrine therapy 58 Nexavar ® 58 PARP inhibitors 58 antitumor activity 57 CCR5 antagonist 57 GM CSF 57 seliciclib 57 EGFr 57 Cotara 57 metastatic hormone refractory 57 ZACTIMA 57 Panzem R NCD 57 VNP#M 57 iniparib 57 tafamidis 57 alkylating agent 57 farletuzumab 57 DXL# 57 HuMax CD# 57 azacitidine 57 Actilon 57 Phase Ib II 57 PI3K inhibitor 57 PS# [001] 57 anti EGFR antibody 57 vandetanib 57 gemcitabine 57 relapsed multiple myeloma 57 amrubicin 57 gefitinib Iressa 57 orally bioavailable 57 panobinostat 57 mTOR inhibitor 57 omacetaxine 57 IMGN# 57 phase IIb trial 57 Campath alemtuzumab 57 targeting CD# 57 talabostat 57 Phase Ib clinical 57 ASA# 57 evaluating tivozanib 57 palifosfamide 57 JAK inhibitor 57 LHRH agonists 57 Azedra 57 nucleoside analog 57 histone deacetylase HDAC inhibitor 57 mertansine 57 luteinizing hormone releasing 57 MDV# 57 vascular disrupting agent 57 CANCIDAS 57 Herceptin trastuzumab 57 Zybrestat 57 hormone refractory prostate cancer 57 trastuzumab DM1 57 HGS ETR2 57 EGFR TKIs 57 ofatumumab 57 Alemtuzumab 57 pomalidomide 57 rituximab 57 gefitinib 57 chemoradiotherapy 57 VitiGam 57 KRN# 57 vinca alkaloid 57 PSN# [002] 57 Cloretazine ® 57 Vidaza 57 Cloretazine 57 oncolytic virus 57 EFAPROXYN 57 glufosfamide 57 perifosine 57 Proxinium TM 57 maraviroc 57 OXi# 57 panitumumab 57 calcitriol 57 Reolysin 57 TELCYTA 57 Quinamed 57 Telintra 57 Dapagliflozin 57 GAP #B# 57 VIDAZA 57 lenalidomide Revlimid R 57 dirucotide 57 humanized monoclonal antibody 57 T#I [002] 57 Theratope 56 Velcade bortezomib 56 oral ridaforolimus 56 OMP #M# 56 bevacizumab Avastin ® 56 Pemetrexed 56 bevacizumab Avastin 56 protease inhibitor PI 56 chemotherapeutic drugs 56 lumiliximab 56 erlotinib Tarceva 56 gamma secretase inhibitor 56 axitinib 56 NVA# 56 Factor VIIa 56 ZK EPO 56 monotherapy 56 docetaxel Taxotere R 56 topotecan 56 nab paclitaxel 56 SUTENT 56 pralatrexate 56 PEP# [003] 56 IGF 1R 56 pazopanib 56 T DM1 56 cetuximab Erbitux 56 zoledronic acid 56 Tyrima 56 IRX 2 56 superficial bladder cancer 56 GRNVAC1 56 Dasatinib 56 custirsen 56 Erbitux cetuximab 56 ponatinib 56 glatiramer acetate 56 RGB # 56 erlotinib Tarceva ® 56 PKC# 56 Orazol 56 teriflunomide 56 EGF receptor 56 otelixizumab 56 pegylated liposomal doxorubicin 56 anticancer agents 56 forodesine 56 Traficet EN 56 viral kinetics 56 trastuzumab 56 relapsed ovarian cancer 56 CA4P 56 erlotinib 56 TOCOSOL Paclitaxel 56 TKIs 56 interferon alfa 56 DAVANAT 56 MyVax R 56 Temsirolimus 56 trastuzumab Herceptin ® 56 GVAX 56 relapsing remitting multiple sclerosis 56 rNAPc2 56 integrase inhibitor 56 PRT# 56 regorafenib 56 IAP inhibitors 56 tesetaxel 56 bendamustine 56 idarubicin 56 DAVANAT ® 56 cancer immunotherapies 56 Curaxin CBLC# 56 oxaliplatin 56 Virulizin R 56 Lenocta 56 bleomycin 56 TAXOTERE R 56 cangrelor 56 atrasentan 56 novel peptide 56 midstage clinical 56 oral prodrug 56 AP# [003] 56 antiangiogenic 56 Reverset 56 cisplatin 56 Gleevec resistant 56 TroVax 56 WT1 56 docetaxel Taxotere ® 56 Irinotecan 56 PEG SN# 56 Elvitegravir 56 GRN# 56 vosaroxin 56 Annamycin 56 cediranib 56 Laquinimod 56 phase IIa clinical 56 HuLuc# 56 cytarabine 56 immunomodulator 56 sunitinib malate 56 KNS # 56 interferon alpha 56 rituximab Rituxan 56 TACI Ig 56 Taxotere chemotherapy 56 TBC# 56 OvaRex ® MAb 56 Phase 2b study 56 CEQ# 56 ELND# 56 INGN 56 Onconase 56 sapacitabine 56 vinorelbine 55 synthetic retinoid 55 standard chemotherapy regimen 55 APOPTONE 55 Atiprimod 55 CTLA 4 55 inhibitor RG# 55 HER2 antibody 55 DACH platinum 55 refractory AML 55 darunavir 55 AMN# [001] 55 PRTX 55 BiovaxID 55 Virulizin ® 55 CR# vcMMAE 55 TMC# [001] 55 Epratuzumab 55 HspE7 55 HQK 55 VEGF receptor 55 Aurora kinase 55 sorafenib tablets 55 Xcytrin 55 resistant ovarian cancer 55 SCH # 55 cetuximab 55 adecatumumab 55 preclinically 55 TG# [001] 55 Pertuzumab 55 Hepatocellular Carcinoma HCC 55 Phase Ib study 55 nilotinib 55 dasatinib Sprycel 55 radiation sensitizer 55 paclitaxel 55 HRPC 55 CYC# 55 protease inhibitor 55 ISTODAX 55 PARP inhibitor 55 lorvotuzumab mertansine 55 Abiraterone acetate 55 vemurafenib 55 GSK# [001] 55 Taxotere docetaxel 55 TYZEKA 55 oxidative stress inducer 55 diabetic neuropathic pain 55 anti TNF 55 dacetuzumab 55 anticancer therapies 55 IFN α 55 APTIVUS r 55 rHuPH# 55 targeted antifolate 55 favorable pharmacokinetic profile 55 IRESSA 55 dose cohorts 55 ritonavir boosted 55 Advexin 55 DFMO 55 Provecta 55 protein kinase inhibitor 55 gemcitabine chemotherapy 55 cytostatic 55 interferon IFN 55 Pazopanib 55 Paclitaxel 55 taxane 55 #I TM# 55 RSD# 55 Hsp# inhibitor 55 HuMax EGFr 55 temozolomide 55 IFN alpha 55 MBP# [001] 55 Taxotere 55 Avastin bevacizumab 55 FTY# 55 fosbretabulin 55 Nexavar sorafenib 55 Phase Ib 55 antitumor effects 55 neoadjuvant chemotherapy 55 Debio 55 Amigal 55 metastatic colorectal 55 xenograft models 55 deforolimus 55 Aflibercept 55 ISIS # 55 Glufosfamide 55 aflibercept 55 Cloretazine R VNP#M 55 TNF inhibitors 55 Marqibo 55 prodrug 55 DAVANAT R 55 adalimumab Humira 55 ustekinumab 55 CIMZIA TM 55 HCV protease inhibitor 55 SAR# [004] 55 Fludara 55 cell lymphoma CTCL 55 BrachySil 55 OncoVEX 55 imatinib resistant 55 CD# monoclonal antibody 55 recurrent glioblastoma multiforme 55 vicriviroc 55 vascular disrupting agents 55 MIRCERA 55 imatinib therapy 55 Gemzar ® 55 ThermoDox R 55 chemotherapeutic agents 55 Fludara ® 55 trabedersen 55 registrational trial 55 LEP ETU 55 Mitoxantrone 55 Carfilzomib 55 atacicept 55 relapsed refractory multiple myeloma 55 IFN beta 55 oral Xeloda 55 darapladib 55 rindopepimut 55 Perifosine 55 anastrozole 55 tyrosine kinase inhibitors 55 Onco TCS 55 PI3K inhibitors 55 clofarabine 55 oral deforolimus 55 paclitaxel Taxol ® 55 FLT3 55 mycophenolate mofetil 55 Phase 2a trial 55 pegylated 55 carfilzomib 55 HER2 positive 55 NXL# 55 TREANDA 55 PDE4 inhibitor 55 prostate cancer AIPC 55 Imprime PGG 55 VAPRISOL 55 trastuzumab Herceptin R 54 malignant pleural mesothelioma 54 interferon beta 1a 54 interferon 54 Arranon 54 EpCAM 54 sorafenib Nexavar ® 54 isoform selective 54 nucleoside 54 nucleoside analogue 54 HDAC inhibitors 54 Triapine R 54 phase IIb 54 BNC# 54 ANG# 54 hedgehog pathway 54 IgG1 monoclonal antibody 54 Aptivus ® 54 polymerase inhibitor 54 thalidomide Thalomid 54 tasisulam 54 Abraxane 54 dutasteride 54 Platinol 54 HCV protease inhibitors 54 Betaferon ® 54 EGFR tyrosine kinase inhibitors 54 metaglidasen 54 SCIg 54 ISF# 54 Leukine 54 selective inhibition 54 Gemzar gemcitabine 54 ALN VSP 54 Ceflatonin R 54 Navelbine 54 lintuzumab 54 Panzem 54 Kahalalide F 54 immune stimulatory 54 golimumab 54 Sorafenib 54 Tamibarotene 54 sargramostim 54 Temozolomide 54 polymerase inhibitors 54 flavopiridol 54 EndoTAGTM 1 54 metastatic castration resistant 54 cutaneous T cell 54 etoposide 54 FOLFOX6 54 metastatic colorectal cancer 54 intravenous bisphosphonates 54 ACZ# 54 PF # [001] 54 Neuvenge 54 histone deacetylase inhibitors 54 cabazitaxel 54 GW# [003] 54 huC# DM4 54 metastatic RCC 54 CLORETAZINE TM VNP#M 54 mipomersen 54 bortezomib Velcade 54 Allovectin 7 54 Anthim 54 epigenetic therapies 54 CCX# 54 maximally tolerated dose 54 CYT# potent vascular disrupting 54 methylnaltrexone 54 humanized antibodies 54 ADI PEG 54 Phase Ia 54 paricalcitol 54 ZOLINZA 54 Clofarabine 54 Tarvacin 54 Vidaza azacitidine 54 zalutumumab 54 RG# [001] 54 palonosetron 54 Xinlay 54 DermaVir Patch 54 midstage studies 54 TRISENOX 54 heavily pretreated 54 Gleevec imatinib 54 Genasense 54 interferon beta 54 trastuzumab emtansine T DM1 54 Rebif ® 54 Allovectin 7 R 54 degarelix 54 IMP# 54 humanized anti 54 proteasome inhibitor 54 dose escalation 54 motesanib 54 Pegasys ® 54 leukemia AML 54 paclitaxel Taxol 54 phase IIb study 54 MNTX 54 retinoid 54 PLK1 SNALP 54 TLR9 agonists 54 TNF α 54 TNFerade 54 radezolid 54 Enzastaurin 54 Zytiga 54 PrevOnco 54 etravirine 54 investigational humanized monoclonal antibody 54 L BLP# 54 docetaxel Taxotere 54 Tarceva TM 54 immunotoxin 54 Hsp# inhibitors 54 Phase Ib clinical trials 54 Dacogen 54 histone deacetylase inhibitor 54 randomized Phase 54 irinotecan 54 carboplatin 54 ADVEXIN 54 dalbavancin 54 investigational monoclonal antibody 54 trastuzumab DM1 T DM1 54 estramustine 54 capecitabine Xeloda R 54 dose escalation trial 54 AZD# 54 ipilimumab 54 HDACi 54 bicalutamide 54 dacarbazine chemotherapy 54 registrational 54 BCR ABL inhibitors 54 taxanes 54 Vectibix panitumumab 54 aprepitant 54 5 FU 54 metastatic melanoma 54 JAK inhibitors 54 sodium glucose cotransporter 54 Cloretazine R 54 entecavir 54 AeroLEF TM 54 Doxil 54 Femara 54 Tykerb 54 gemcitabine Gemzar 54 bortezomib Velcade R 54 proteasome inhibitor bortezomib 54 eltrombopag 54 satraplatin 54 exemestane 54 antibody 54 phase Ib 54 virus HCV protease inhibitor 54 ProSavin 54 teduglutide 54 Romidepsin 54 Faslodex 54 somatostatin analogue 54 MYDICAR ® 54 PROVENGE 54 tipranavir 54 Alocrest 54 TLR9 agonist 54 Panzem R 54 panitumumab Vectibix 54 antiangiogenic therapy 54 Voreloxin 54 Neulasta ® 54 hematological cancers 54 relapsing remitting MS 54 nimotuzumab 54 ATL/TV# 54 Phase 1b trial 54 GLP toxicology studies 54 Xyotax 54 Homspera 54 bapineuzumab 53 Ambrisentan 53 tenofovir Viread 53 IV bisphosphonates 53 Corlux 53 ENMD # 53 Mipomersen 53 DAPT 53 PEG Interferon lambda 53 imatinib 53 idraparinux 53 OHR/AVR# 53 antisense drug 53 afatinib 53 pegylated interferon alpha 53 clusterin 53 NNRTIs 53 doxorubicin 53 CRLX# 53 dasatinib Sprycel ® 53 Treanda 53 anti CD3 53 Docetaxel 53 Tarceva erlotinib 53 tolerability 53 FTY# fingolimod 53 Vectibix 53 Carboplatin 53 carboplatin paclitaxel 53 cytotoxic chemotherapy 53 RhuDex ® 53 LHRH agonist 53 Jevtana 53 octreotide 53 OMAPRO 53 AVE# 53 pradefovir 53 gemcitabine cisplatin 53 Revlimid lenalidomide 53 refractory multiple myeloma 53 NSCLC 53 Atrasentan 53 Elotuzumab 53 ONTAK 53 tivozanib 53 Aromasin 53 PKCi 53 Scancell 53 refractory CLL 53 Intravenous CP 53 relapsing multiple sclerosis 53 Etoposide 53 APTIVUS 53 Phase III clinical trials 53 Everolimus 53 Imatinib 53 daclizumab 53 BCX# 53 hormone LHRH agonist 53 Exenatide 53 Ophena TM 53 Liraglutide 53 figitumumab 53 Alzhemed TM 53 Allovectin 7 ® 53 HSP# inhibitor 53 bosutinib 53 AAG geldanamycin analog 53 letrozole 53 LAF# 53 Omapro 53 TORISEL 53 visilizumab 53 OncoGel 53 RAV# 53 trastuzumab emtansine 53 R#/MEM # 53 HDAC inhibition 53 HGS ETR1 mapatumumab 53 angiogenesis inhibition 53 Herceptin 53 anti CD# antibodies 53 monoclonal antibody MAb 53 cyclosporin 53 huN# DM1 53 cetuximab Erbitux R 53 imatinib Gleevec 53 delta isoform 53 AA amyloidosis 53 eosinophilic asthma 53 deacetylase inhibitors 53 veltuzumab 53 chronic myeloid leukemia CML 53 danoprevir 53 Vidofludimus 53 Fulvestrant 53 dose cytarabine 53 OvaRex R 53 aromatase inhibitor 53 Tavocept 53 hematologic malignancies 53 recurrent GBM 53 VEGF inhibitors 53 Daclizumab 53 natalizumab 53 relapsed MM 53 ON #.Na 53 BRIM3 53 TELINTRA 53 velafermin 53 immune modulatory 53 talactoferrin 53 metastatic renal cell 53 EGFR inhibitor 53 Pralatrexate 53 Onalta 53 telomerase therapeutic 53 Cethromycin 53 metastatic malignant melanoma 53 lesinurad 53 investigational compound 53 tecarfarin 53 myeloma cells 53 ISEL 53 Luteinizing Hormone Releasing Hormone 53 Fx #A 53 sustained virologic response 53 EZN 53 dacarbazine 53 Onrigin 53 Canvaxin 53 cleavable linker 53 elvucitabine 53 Phase #b/#a clinical 53 CIMZIA ™ 53 targeted radiotherapeutic 53 Hsp# inhibition 53 rhThrombin 53 follicular non 53 PGE2 53 chemotherapeutics 53 monoclonal 53 StemEx R 53 Taxol paclitaxel 53 anticancer therapy 53 CCR5 antagonists 53 milatuzumab 53 tamibarotene 53 Velcade 53 metastatic sarcoma 53 Maraviroc 53 TYKERB 53 Azilect ® 53 TNFa 53 Elesclomol 53 nucleoside analogs 53 Squalamine 53 Amphinex ® 53 telaprevir dosed 53 demethylating agents 53 SinuNase 53 OMP #R# 53 Telaprevir 53 cabozantinib 53 Myocet 53 imatinib mesylate 53 JAK1 53 ospemifene 53 velafermin belinostat 53 SIR Spheres 53 clodronate 53 durable remissions 53 Plicera 53 insulin sensitizer 53 Afatinib 53 ThermoDox 53 Phenoptin 53 blinatumomab 53 Ixabepilone 53 synthetic peptide 53 oral mTOR inhibitor 53 Ceplene/IL-2 53 ganciclovir 53 chemotherapy cisplatin 53 Phase 2b trial 53 oral antiviral 53 IIa trial 53 ALK inhibitor 53 ocrelizumab 53 tenofovir emtricitabine 53 LEUKINE 53 REYATAZ R 53 TLK# 53 EGFR inhibitors 53 sipuleucel T 53 fluorouracil 53 rFVIII 53 Archexin 53 Doxil ® 53 antitumor 53 LHRH receptor positive 53 Phase 1b 53 TAFA# 53 chlorambucil 53 5FU 53 doxorubicin docetaxel 53 Troxatyl 53 etanercept 53 fluoropyrimidine 53 mesylate 53 oxaliplatin Eloxatin 53 cardiac toxicity 53 nonsmall cell lung cancer 53 ara C 53 Ontak 53 BEXXAR 53 Azixa 53 relapsed leukemia 53 B CLL 53 cancer immunotherapy 53 oral methylnaltrexone 53 ongoing Phase 1b 53 corticosteroid dexamethasone 53 anti angiogenic drugs 52 Copegus ribavirin 52 elvitegravir 52 Gemcitabine 52 MabCampath 52 lenalidomide 52 anidulafungin 52 Tumor Necrosis Factor 52 pegfilgrastim 52 monoclonal antibody 52 cinacalcet 52 Cetuximab 52 clinical trials 52 JAK3 52 pegylated interferon alfa 2a 52 immune modulating 52 CD# antibodies 52 L MTP PE 52 Ixempra 52 Actemra 52 Omnitarg 52 CD# mAb 52 Phase IIb trial 52 hormone deprivation 52 tezampanel 52 Nanobody ® 52 Epothilones 52 Vicinium TM 52 ALN TTR 52 LHRH 52 oblimersen 52 Viramidine 52 Ozarelix 52 Aurora kinase inhibitor 52 MAXY G# 52 NRTIs 52 doxorubicin Transdrug ® 52 biologic therapy 52 administered subcutaneously 52 Lapatinib 52 alemtuzumab 52 radiolabeled TM# 52 bortezomib Velcade ® 52 antimetabolite 52 glioblastoma multiforme GBM 52 tubulin inhibitor 52 Xeloda capecitabine 52 vismodegib 52 AMPK activators 52 metastatic castrate resistant 52 Interferon alpha 52 INTELENCE 52 Novartis Zometa 52 BRIM2 52 nonclinical studies 52 S/GSK# 52 microtubule inhibitor 52 cis retinoic acid 52 selective inhibitors 52 AZILECT R 52 clinical trial 52 reslizumab 52 Genasense ® 52 dabigatran etexilate 52 Zerenex 52 eritoran 52 IL# PE#QQR 52 irinotecan chemotherapy 52 Rituximab 52 SUCCEED trial 52 TRAIL receptor 52 pemetrexed 52 dose cohort 52 Golimumab 52 CTAP# Capsules 52 exon skipping 52 colon carcinoma 52 REOLYSIN ® 52 HDAC inhibitor 52 IAP inhibitor 52 PROSTVAC TM 52 K ras mutations 52 olmesartan 52 Fodosine 52 colorectal liver metastases 52 chronic lymphocytic leukemia CLL 52 ALN TTR# 52 JAK2 inhibitor 52 Pegylated Interferon 52 ibandronate 52 uric acid lowering 52 Teriflunomide 52 dexpramipexole 52 immunotherapeutic 52 Trabectedin 52 telaprevir